🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 28 of 857 · Phase 3 first, then by program name

  1. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Late-onset Pompe Disease

    phase 3 small molecule terminated

    1 trial

  2. BMN165 20mg/day

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule completed

    1 trial

  3. BMS-986353

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis

    phase 3 small molecule active

    1 trial

  4. BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech SE

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  5. BNT327 20 mg ml, BNT327 50 mg ml, PEMBROLIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. BNT327 50 mg ml, DURVALUMAB, BNT327 20 mg ml

    Bristol-Myers Squibb Australia Pty Ltd

    Unresectable Stage III non-small cell lung cancer without progression

    phase 3 small molecule active

    1 trial

  7. BOTOX

    AbbVie

    Masseter Muscle Prominence

    phase 3 small molecule completed

    1 trial

  8. BOTOX 50 UNITÉS ALLERGAN, poudre pour solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 small molecule active

    1 trial

  9. BRUKINSA 80 mg hard capsules, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, IMBRUVICA 140 mg hard capsules, Lisaftoclax, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  10. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  11. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  12. BULEVIRTIDE, BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis D Infection

    phase 3 small molecule active

    1 trial

  13. BXCL501

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 3 small molecule completed

    1 trial

  14. BXCL501

    BioXcel Therapeutics

    Agitation

    phase 3 small molecule completed

    4 trials

  15. BYL719, BYL719, Placebo to BYL719 125 mg film-coated tablets, Placebo to BYL719 200 mg film-coated tablets, Placebo to BYL719 50 mg film-coated tablets, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  16. Bacillus Calmette Guerin and interferon alpha

    Hospital Authority, Hong Kong

    Carcinoma of Urinary Bladder, Superficial

    phase 3 small molecule completed

    1 trial

  17. BaidI Quzhi granule

    Universal Integrated

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  18. Balcinrenone+Dapagliflozin, Balcinrenone+Dapagliflozin, Forxiga, Balcinrenone+Dapagliflozin, Forxiga 10 mg film-coated tablets

    AstraZeneca AB

    Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death

    phase 3 small molecule active

    1 trial

  19. Baloxavir Marboxil

    Hoffmann-La Roche

    Influenza

    phase 3 small molecule completed

    1 trial

  20. Balugrastim

    Teva Pharma GmbH

    Chemotherapy-induced Neutropenia

    phase 3 mab completed

    1 trial

  21. Bardoxolone methyl

    Biogen

    Pulmonary Hypertension

    phase 3 small molecule terminated

    1 trial

  22. Baricitinib

    Eli Lilly and Company

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  23. Baricitinib

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule terminated

    1 trial

  24. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources